Brought to you by 
OncoMethylome, Schering-Plough in pharmacogenomics deal
17 Jun 2014
Executive Summary
OncoMethylome Sciences SA (clinical diagnostics for cancer) has licensed Schering-Plough worldwide, non-exclusive rights to its MGMT (methylguanine-methyltransferase) assays and technology to measure the methylation status of the MGMT gene in glioblastoma multiforme (GBM) patients currently being treated with Schering's Temodar (temozolomide), an oral alkylating agent.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OncoMethylome, Schering-Plough in pharmacogenomics deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice